Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial of GB491 Combined With Fulvestrant in Subjects With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed on Prior Endocrine Therapy

NCT05054751 is registered in ClinicalTrials.gov with Genor Biopharma Co., Ltd. as lead sponsor.

NCT NCT05054751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05054751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial of GB491 Combined With Fulvestrant in Subjects With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed on Prior Endocrine Therapy
Lead sponsor
Genor Biopharma Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 10, 2021
Completion date
March 30, 2024
Enrollment
275 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic breast cancer